Assignee
INTARCIA THERAPEUTICS INC
US49 patents
Top patents by PatentIndex Score
US8992962B2Mar 31, 2015
Two-piece, internal-channel osmotic delivery system flow modulator
INTARCIA THERAPEUTICS INC29 citations97
US8372424B2Feb 12, 2013
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
INTARCIA THERAPEUTICS INC81 citations97
US7879028B2Feb 1, 2011
Osmotic delivery systems and piston assemblies for use therein
INTARCIA THERAPEUTICS INC72 citations97
US7682356B2Mar 23, 2010
Osmotic delivery systems and piston assemblies for use therein
INTARCIA THERAPEUTICS INC84 citations97
US7655257B2Feb 2, 2010
Sustained delivery of an active agent using an implantable system
INTARCIA THERAPEUTICS INC50 citations97
US8367095B2Feb 5, 2013
Two-piece, internal-channel osmotic delivery system flow modulator
INTARCIA THERAPEUTICS INC33 citations96
US8052996B2Nov 8, 2011
Two-piece, internal-channel osmotic delivery system flow modulator
INTARCIA THERAPEUTICS INC37 citations96
US9095553B2Aug 4, 2015
Solvent/polymer solutions as suspension vehicles
INTARCIA THERAPEUTICS INC27 citations95
US7919109B2Apr 5, 2011
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
INTARCIA THERAPEUTICS INC35 citations95
US9682127B2Jun 20, 2017
Osmotic delivery device comprising an insulinotropic peptide and uses thereof
INTARCIA THERAPEUTICS INC21 citations94
US7731947B2Jun 8, 2010
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
INTARCIA THERAPEUTICS INC46 citations94
US9572889B2Feb 21, 2017
Devices, formulations, and methods for delivery of multiple beneficial agents
INTARCIA THERAPEUTICS INC23 citations93
US9526763B2Dec 27, 2016
Solvent/polymer solutions as suspension vehicles
INTARCIA THERAPEUTICS INC24 citations93
USD840030SFeb 5, 2019
Implant placement guide
INTARCIA THERAPEUTICS INC25 citations92
US8048438B2Nov 1, 2011
Stable non- aqueous single phase viscous vehicles and formulations utilizing such vehicles
INTARCIA THERAPEUTICS INC35 citations92
US7407499B2Aug 5, 2008
Osmotic pump with self-retaining, fast-start membrane plug
INTARCIA THERAPEUTICS INC39 citations92
US9889085B1Feb 13, 2018
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
INTARCIA THERAPEUTICS INC18 citations91
US9539200B2Jan 10, 2017
Two-piece, internal-channel osmotic delivery system flow modulator
INTARCIA THERAPEUTICS INC23 citations91
US8343140B2Jan 1, 2013
Devices, formulations, and methods for delivery of multiple beneficial agents
INTARCIA THERAPEUTICS INC30 citations91
US7964183B2Jun 21, 2011
Composition and dosage form comprising a particle formulation and suspending vehicle
INTARCIA THERAPEUTICS INC28 citations90
US7959938B2Jun 14, 2011
Polyoxaester suspending vehicles for use with implantable delivery systems
INTARCIA THERAPEUTICS INC37 citations89
US7655254B2Feb 2, 2010
Implantable device for continuous delivery of interferon
INTARCIA THERAPEUTICS INC44 citations89
US7316680B2Jan 8, 2008
Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
INTARCIA THERAPEUTICS INC35 citations89
US7727519B2Jun 1, 2010
Method for treating hepatitis C virus with omega interferon
INTARCIA THERAPEUTICS INC34 citations87
USD835783SDec 11, 2018
Implant placement guide
INTARCIA THERAPEUTICS INC5 citations82
US7011851B2Mar 14, 2006
Oxidized collagen formulations for use with non-compatible pharmaceutical agents
INTARCIA THERAPEUTICS INC14 citations80
USD962433SAug 30, 2022
Implant placement guide
INTARCIA THERAPEUTICS INC1 citations71
USD912249SMar 2, 2021
Implant removal tool
INTARCIA THERAPEUTICS INC2 citations71
US10925639B2Feb 23, 2021
Implant placement and removal systems
INTARCIA THERAPEUTICS INC2 citations71
USD860451SSep 17, 2019
Implant removal tool
INTARCIA THERAPEUTICS INC1 citations71
US10159714B2Dec 25, 2018
Compositions, devices and methods of use thereof for the treatment of cancers
INTARCIA THERAPEUTICS INC2 citations70
US11840559B2Dec 12, 2023
Glucagon-receptor selective polypeptides and methods of use thereof
INTARCIA THERAPEUTICS INC1 citations69
US11214607B2Jan 4, 2022
Glucagon-receptor selective polypeptides and methods of use thereof
INTARCIA THERAPEUTICS INC3 citations69
US10501517B2Dec 10, 2019
Glucagon-receptor selective polypeptides and methods of use thereof
INTARCIA THERAPEUTICS INC4 citations69
US11739134B2Aug 29, 2023
Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
INTARCIA THERAPEUTICS INC2 citations68
US11246913B2Feb 15, 2022
Suspension formulation comprising an insulinotropic peptide
INTARCIA THERAPEUTICS INC0 citations62
US11654183B2May 23, 2023
Methods comprising continuous administration of exenatide and co-administration of a drug
INTARCIA THERAPEUTICS INC1 citations59
US12122816B2Oct 22, 2024
Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
INTARCIA THERAPEUTICS INC0 citations58
US12042557B2Jul 23, 2024
Rapid establishment and/or termination of substantial steady-state drug delivery
INTARCIA THERAPEUTICS INC0 citations58
US12018059B2Jun 25, 2024
Human amylin analog polypeptides and methods of use
INTARCIA THERAPEUTICS INC0 citations58
USD933219SOct 12, 2021
Implant removal tool and assembly
INTARCIA THERAPEUTICS INC0 citations58
US10527170B2Jan 7, 2020
Osmotic delivery systems and piston assemblies for use therein
INTARCIA THERAPEUTICS INC0 citations52
US10363287B2Jul 30, 2019
Method of manufacturing an osmotic delivery device
INTARCIA THERAPEUTICS INC0 citations52
US12084485B2Sep 10, 2024
Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use
INTARCIA THERAPEUTICS INC0 citations50
US10441528B2Oct 15, 2019
Devices, formulations, and methods for delivery of multiple beneficial agents
INTARCIA THERAPEUTICS INC0 citations50
US10835580B2Nov 17, 2020
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
INTARCIA THERAPEUTICS INC0 citations49
US10583080B2Mar 10, 2020
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
INTARCIA THERAPEUTICS INC0 citations49
US10869830B2Dec 22, 2020
Rapid establishment and/or termination of substantial steady-state drug delivery
INTARCIA THERAPEUTICS INC0 citations48
US10231923B2Mar 19, 2019
Rapid establishment and/or termination of substantial steady-state drug delivery
INTARCIA THERAPEUTICS INC0 citations48